Bio Pharma Dive
OCTOBER 3, 2023
The deal will hand Lilly a pipeline of experimental radioligand therapies, including a potential rival to Novartis’ Pluvicto, as well as a valuable manufacturing plant.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 3, 2023
If you believe the headlines, seaweeds can do almost anything from storing tons of carbon and stopping cows from belching methane, to making biofuels and renewable plastics – all while sustaining vibrant coastal ecosystems and feeding communities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 3, 2023
The longtime partners believe that, by combining their technologies, they can create “in vivo” genetic medicines for nervous system and muscular disorders.
Pharmaceutical Technology
OCTOBER 3, 2023
Drug manufacturer Viatris has announced the divestment of a number of businesses owned by the company in a $.37bn deal.
Bio Pharma Dive
OCTOBER 3, 2023
Only two of the eight biotech companies that priced offerings since July 1 trade at or above their debut share price, according to data from BioPharma Dive.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 3, 2023
Indian medical devices companies are increasingly looking to invest in innovation for developing products that help to minimize environmental footprint. Also companies like the healthtech startup HaystackAnalytics are engaged in developing India’s first Universal Infectious Disease (UID) genomic test, which highlights the need to put in place preventive health strategies.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
OCTOBER 3, 2023
Sanofi has signed an agreement with Janssen Pharmaceuticals for potential first-in-class vaccine against extraintestinal pathogenic E coli.
Antidote
OCTOBER 3, 2023
Clinical trials are an integral part of the medical industry, as they are required for any new treatment to be approved. Every medicine used today, whether prescription or over the counter, is a result of the rigorous research process that is a clinical trial — and for these trials to take place, volunteers are vital.
Pharmaceutical Technology
OCTOBER 3, 2023
The UK MHRA has granted authorisation for GSK's Jemperli (dostarlimab) to treat adult patients with certain endometrial cancer types.
BioSpace
OCTOBER 3, 2023
New Phase I/II trial results show that one more type 1 diabetes patient achieved insulin independence after treatment with Vertex Pharmaceuticals’ investigational stem cell therapy VX-880.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
OCTOBER 3, 2023
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
Fierce Pharma
OCTOBER 3, 2023
Four months after GSK settled a key case in California over its heartburn medication Zantac, AstraZeneca is following suit, agreeing to resolve personal injury claims over its heartburn drugs Nexiu | Four months after GSK settled a key case in California over its heartburn medication Zantac, AstraZeneca is following suit, agreeing to resolve personal injury claims over its heartburn drugs Nexium and Prilosec.
Pharmaceutical Technology
OCTOBER 3, 2023
Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for Rivfloza (nedosiran) injection
Fierce Pharma
OCTOBER 3, 2023
As Galderma attempts to round out its injectable aesthetics portfolio with approvals to resolve crow’s feet and frown lines, the FDA spotted a few manufacturing wrinkles in its RelabotulinumtoxinA | The agency spotted issues relating to chemistry, manufacturing and controls (CMC) processes in the company's application for its liquid botulinum toxin type A.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
OCTOBER 3, 2023
Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers.
Pharma Times
OCTOBER 3, 2023
The Cancer Hub aims to create a world-leading ecosystem for cancer research - News - PharmaTimes
Pharmaceutical Technology
OCTOBER 3, 2023
Nitric oxide is under clinical development by NOxy Health Products and currently in Phase I for Diabetic Foot Ulcers.
Outsourcing Pharma
OCTOBER 3, 2023
The U.K. startup Automata Technologies has bagged $40 million in a funding round to expand its workforce and the geographic reach of its life sciences lab automation technology.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
OCTOBER 3, 2023
BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.
pharmaphorum
OCTOBER 3, 2023
How the rise of medical device use in pharma R&D is driving wearable technology in healthcare and revolutionising the medical industry Mike.
Pharmaceutical Technology
OCTOBER 3, 2023
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.
BioSpace
OCTOBER 3, 2023
In its briefing document for Thursday’s FDA advisory committee meeting, the regulator contends that the company’s confirmatory CodeBreaK 200 trial for Lumakras is not an “adequate and well-controlled” study.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharmaceutical Technology
OCTOBER 3, 2023
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Natural Killer Cell Lymphomas.
BioSpace
OCTOBER 3, 2023
The French pharma paid $500 million upfront, with up to $1 billion in future milestone payments, to co-develop and co-commercialize Teva’s Phase II anti-TL1A antibody for inflammatory bowel disease.
Pharmaceutical Technology
OCTOBER 3, 2023
Super DC Vaccine is under clinical development by Shanghai Cell Therapy Group and currently in Phase I for Solid Tumor.
BioSpace
OCTOBER 3, 2023
The call to develop therapeutics that interfere with aging, helping people live longer, healthier lives, is increasing—and experts say the market opportunity is high.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
OCTOBER 3, 2023
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.
Fierce Pharma
OCTOBER 3, 2023
After a confirmatory trial flop this past summer, Takeda is calling it quits on its targeted non-small cell lung cancer (NSCLC) drug Exkivity. | Takeda will work with the FDA to chart a voluntary withdrawal of Exkivity in the U.S., where the drug is approved for certain adult lung cancer patients whose disease has progressed on or after platinum-based chemotherapy.
Pharmaceutical Technology
OCTOBER 3, 2023
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.
BioSpace
OCTOBER 3, 2023
AbbVie, Amgen, Gilead, Merck and Novartis are among the 31 members that have formed the Partnership for the U.S. Life Science Ecosystem to push back against federal antitrust reforms.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
251 
Let's personalize your content